Key recent developments include the company’s IPO completion in early 2025, raising $6.9 million gross proceeds, and receipt of a Nasdaq delinquency letter for non-compliance with listing requirements in May 2025.

• Zhengye Biotechnology Holding Limited closed its initial public offering on January 8, 2025, raising $6 million on Nasdaq [N3].
• The company completed its IPO with full over-allotment option exercised, raising total gross proceeds of $6.9 million as of January 14, 2025 [N2].
• Zhengye Biotechnology Holding Limited received a Nasdaq delinquency letter for non-compliance with listing requirements on May 23, 2025 [N1].

The company has completed its IPO, providing capital to support research and development and operational activities. Its diversified vaccine portfolio across multiple livestock species and ongoing R&D projects may support product development and market responsiveness. The reduction in customer concentration risk and efforts to strengthen internal controls indicate management's focus on operational improvements. The company’s established relationships with research institutes and technology licensing agreements provide a foundation for innovation.

Revenue has declined significantly due to adverse market conditions in the hog industry and government policies reducing demand for swine vaccines. The company reported a net loss of approximately $11.9 million in 2025 and faces liquidity constraints with a low cash ratio. A material weakness in internal controls over financial reporting remains under remediation, posing risks to financial reporting reliability. The receipt of a Nasdaq delinquency letter for non-compliance with listing requirements highlights regulatory and compliance risks. Customer concentration, while reduced, remains a factor to monitor.

Zhengye Biotechnology's moat is based on its specialized focus on veterinary vaccines for livestock, including swine, poultry, and sheep. The company benefits from established technology licensing agreements and research collaborations with veterinary research institutes. However, the company faces market volatility in the livestock sector and regulatory challenges, which may impact its competitive position. Its ongoing investment in research and development supports product innovation, but customer concentration and market demand fluctuations present challenges to sustained competitive advantage.

• Market Dependency and Volatility: The company’s revenue is sensitive to market conditions in the livestock industry, particularly the hog market, which experienced downturns and government policy impacts in 2025 leading to reduced demand for vaccines.
• Financial Reporting and Internal Controls: A material weakness in internal control over financial reporting due to insufficient accounting staff expertise in U.S. GAAP and SEC reporting has been identified, with ongoing remediation efforts but not yet fully addressed.
• Regulatory Compliance: The company received a Nasdaq delinquency letter for non-compliance with listing requirements, indicating potential risks related to regulatory adherence and listing standards.
• Liquidity and Financial Performance: The company reported a net loss in 2025 and has limited cash reserves with a low cash ratio, which may constrain operational flexibility and capital expenditures.

• Zhengye Biotechnology Holding Ltd completed its initial public offering (IPO) on January 8, 2025, raising gross proceeds of $6.9 million, with net proceeds of approximately $6.0 million after expenses and underwriting discounts, as disclosed in the Form 20-F filing [S1].
• The company manufactures and sells veterinary vaccines, primarily for livestock, including swine, poultry, and sheep vaccines [S1].
• Revenue for the fiscal year ended December 31, 2025, was approximately $16.6 million (RMB116.4 million), a decline from prior years, primarily due to a downturn in the hog market and government policies affecting demand for swine vaccines [S1].
• Net loss for the year ended December 31, 2025, was approximately $11.9 million (RMB83.0 million) [S1].
• The company’s research and development expenses increased to approximately $2.6 million (RMB18.0 million) in 2025, reflecting increased R&D projects [S1].
• Sales and marketing expenses were approximately $6.3 million (RMB43.9 million) in 2025, and general and administrative expenses were approximately $4.4 million (RMB31.0 million) [S1].
• The company’s liquidity as of December 31, 2025, included cash and equivalents of approximately $2.5 million and short-term investments of $0.2 million, with a current ratio of 1.14 and a cash ratio of 0.16 [S1].
• The company has a material weakness in internal control over financial reporting due to a lack of accounting staff with appropriate U.S. GAAP and SEC reporting knowledge, with ongoing remediation efforts including recruitment and training [S1].
• The company’s largest customer concentration has decreased, with the largest customer accounting for 13.7% of revenues in 2025, down from higher concentrations in prior years [S1].
• The company received a Nasdaq delinquency letter for non-compliance with listing requirements as of May 23, 2025 [N1].
• The company’s IPO was underwritten by Kingswood Capital Partners, LLC, which exercised the full over-allotment option [N2][N3].